Alaunos Therapeutics, Inc. (TCRT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 16, 2024, by Alaunos Therapeutics, Inc., a Delaware corporation. The report details a corporate action approved by the Board of Directors on June 26, 2024, and by stockholders at the Annual Meeting on June 6, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a notice of a capital structure change.
Material Changes
The primary material event is the implementation of a reverse stock split of the Company's common stock at a ratio of 1-for-10. Key details include:
- Effective Date: July 17, 2024, at 5:00 p.m. Eastern Time.
- Mechanism: Every 10 shares of issued and outstanding common stock will be automatically combined into 1 share.
- Trading Resumption: Trading will resume on July 18, 2024, on The Nasdaq Stock Market under the symbol "TCRT" on a split-adjusted basis.
- New CUSIP: 98973P309.
- Exchange Agent: Equiniti Trust Company is acting as the exchange agent to facilitate the conversion of pre-split shares to post-split shares.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation of the Charter Amendment by reference. The reverse split was authorized within a range of 1-for-5 to 1-for-15, with the Board selecting the 1-for-10 ratio.
Investor Verification Checklist
- Verify the number of shares held prior to the July 17, 2024, effective date to calculate the post-split share count.
- Confirm the new CUSIP number (98973P309) for trading purposes starting July 18, 2024.
- Review instructions from Equiniti Trust Company regarding the exchange of pre-split certificates, if applicable.
- Check the Third Amended and Restated Certificate of Incorporation (Exhibit 3.1) for complete legal terms of the amendment.